Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS16
PHASE 3 / 2-310
RECRUITING11
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO0%
Delay Index: of 6 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| NCT06886126 NCT06886126 |
P2 | Recruiting | Obesity | 240 | 2025-09-23 |
| HDM1005 1 NCT07109700 |
P2 | Recruiting | Type 2 Diabetes | 216 | 2026-01-31 |
| HDM1702 NCT07036172 |
P3 | Recruiting | Obesity Control | 460 | 2026-04 |
| HDM1002 200mg, oral, once daily, 52 weeks NCT06885021 |
P3 | Not yet recruiting | Overweight and Obesity | 780 | 2026-05-30 |
| HDM1005 1 NCT07279194 |
P3 | Recruiting | Obesity & Overweight | 825 | 2026-09-20 |
| HDM1002 200 mg NCT07193459 |
P3 | Recruiting | Type 2 Diabetes | 360 | 2026-10-10 |
| HDM1005 dose level 1 NCT07521631 |
P2 | Recruiting | Obesity | 372 | 2027-02-04 |
| HDM1002 100 mg NCT07082114 |
P3 | Recruiting | Type 2 Diabetes | 800 | 2027-02-16 |
| Roflumilast Foam 0.3% NCT07683806 |
P3 | Recruiting | Seborrheic Dermatitis | 309 | 2027-06-30 |
| HDM1005 1 NCT07394114 |
P3 | Recruiting | Type 2 Diabetes | 240 | 2027-08-28 |
| HDM1005 1 NCT07417306 |
P3 | Not yet recruiting | Type 2 Diabetes | 912 | 2027-08-30 |
| HDM2005 NCT07124936 |
P1/2 | Recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 97 | 2027-10-26 |
| HDM2017 NCT07621159 |
P1/2 | Not yet recruiting | Colorectal Cancer Metastatic | 120 | 2027-11-01 |
| HDM1005 NCT07787260 |
P3 | Not yet recruiting | Obstructive Sleep Apnea (OSA) and Obesity | 200 | 2028-03 |
| HDM1005 NCT07794397 |
P3 | Not yet recruiting | Obstructive Sleep Apnea (OSA) and Obesity | 200 | 2028-09 |
| HDM2017 NCT07805551 |
P1/2 | Recruiting | CRC, Colorectal Cancer | 220 | 2030-08 |